BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer, including the first off-the-shelf personalized approach to immunotherapy. The company recently achieved positive proof-of-concept in a Phase I/IIa clinical trial for its lead product candidate, Bria-IMT™, in patients with advanced breast cancer (ClinicalTrials.gov as NCT03066947). The trial was being conducted along with the co-development of BriaDX™, the company’s companion diagnostic test. Currently, BriaCell is conducting an FDA approved combination study of Bria-IMT™ with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] for patients with advanced breast cancer (ClinicalTrials.gov as NCT03328026). Capitalizing on insights gained with Bria-IMT™, BriaCell is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for the treatment for advanced stage Breast Cancer. Finally, BriaCell’s small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases.